Goldman Sachs BDC, Inc. (GSBD)

Blueprint Medicines Stock Forecast

Stock Price Forecast

The 2 analysts that cover Blueprint Medicines stock have a consensus rating of "Sell" and an average price target of $12, which forecasts a 8.70% increase in the stock price over the next year. The lowest target is $10 and the highest is $14.

Price Target: $12.00 (+8.70%)

Analyst Consensus: Sell

Target	Low	Average	Median	High
Price	$10	$12	$14	$14
Change	-9.42%	+8.70%	+26.81%	+26.81%

* Price targets were last updated on Apr 28, 2025.

Analyst Ratings

The average analyst rating for Blueprint Medicines stock is "Sell". This means that analysts believe this stock is likely to lead to lower returns than market as a whole.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	0	0	0	0	0	0
Buy	0	0	0	0	0	0
Hold	3	3	1	1	1	1
Sell	0	0	1	1	1	1
Strong Sell	0	0	0	0	0	0
Total	3	3	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Finian O'Shea Wells Fargo	Wells Fargo	Sell Maintains $12 → $10	Sell	Maintains	$12 → $10	-9.42%	Apr 28, 2025
Mark Hughes Truist Securities	Truist Securities	Hold Maintains $16 → $14	Hold	Maintains	$16 → $14	+26.81%	Aug 12, 2024
Finian O'Shea Wells Fargo	Wells Fargo	Sell → Hold Upgrades $14 → $12	Sell → Hold	Upgrades	$14 → $12	+8.70%	Aug 12, 2024
Finian O'Shea Wells Fargo	Wells Fargo	Hold → Sell Downgrades $15 → $14	Hold → Sell	Downgrades	$15 → $14	+26.81%	May 29, 2024
Timothy O'Shea Wells Fargo	Wells Fargo	Hold Maintains $15 → $15	Hold	Maintains	$15 → $15	+35.87%	Jan 29, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

386.34M

Decreased by -11.06%

from 434.37M

Revenue Next Year

373.45M

Decreased by -3.34%

from 386.34M

EPS This Year

1.62

Increased by 195.36%

from 0.55

EPS Next Year

1.43

Decreased by -11.50%

from 1.62

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	172.96M	346.98M	357.45M	454.91M	434.37M	386.34M	373.45M	358.69M
Revenue Growth	17.45%	100.61%	3.02%	27.27%	-4.52%	-11.06%	-3.34%	-3.95%
EPS	3.26	1.89	0.54	1.81	0.55	1.62	1.43	1.38
EPS Growth	264.12%	-42.04%	-71.58%	236.23%	-69.69%	195.36%	-11.50%	-3.91%
Forward PE	-	-	-	-	-	6.82	7.70	8.02
No. Analysts	-	-	-	-	-	6	6	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	410.9M	401.6M	369.2M
Avg	386.3M	373.5M	358.7M
Low	363.8M	339.9M	344.6M

Revenue Growth

Revenue Growth	2025	2026	2027
High	-5.4%	4.0%	-1.1%
Avg	-11.1%	-3.3%	-4.0%
Low	-16.3%	-12.0%	-7.7%

EPS Forecast

EPS	2025	2026	2027
High	1.70	1.53	1.42
Avg	1.62	1.43	1.38
Low	1.50	1.26	1.32

EPS Growth

EPS Growth	2025	2026	2027
High	210.3%	-5.3%	-1.1%
Avg	195.4%	-11.5%	-3.9%
Low	173.5%	-21.9%	-7.7%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.